As PPARγ full agonists, thiazolidinediones (TZDs), such as rosiglitazone and pioglitazone, have been widely used in treating type 2 diabetes mellitus due to their potent insulin-sensitizing effects [8]. Here, INS is linked to diabetes mellitus.